Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone marrow transplant in the US, buoyed by top-line data from a pivotal trial.

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Actinium Pharmaceuticals Stock Down 4.9 % Shares of ATNM opened at $1.17 on Friday. The stock has a market capitalization of $36.50 million, a P/E ratio of -0.84 and a beta of 0.13. The firm has a ...

Actinium Pharmaceuticals (NYSE:ATNM) closed the most recent trading day at $11.16, moving -1.06% from the previous trading session. This change lagged the S&P 500's ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $4.00. The company’s ...